Durable response to combination therapy including staphylococcal protein A immunoadsorption in life-threatening refractory autoimmune hemolysis

Transfusion. 2002 Sep;42(9):1217-20. doi: 10.1046/j.1537-2995.2002.00193.x.

Abstract

Background: Few therapeutic options are available for severe, life-threatening, refractory autoimmune hemolytic anemia.

Case report: A 53-year-old 110-kg man was seen with acute onset of symptomatic severe anemia with syncope, unstable angina, and jaundice. His nadir Hct was 8.3 percent with a peak total bilirubin of 44 mg per dL. The DAT was positive but the IAT was negative. Elution studies demonstrated an IgG pan-agglutinin antibody reactive at 37 degrees C. Treatment with high-dose corticosteroids and IVIG was instituted. An accessory spleen measuring 2 cm was identified and surgically removed, but the patient continued to have intense hemolysis. Cyclophosphamide at 200 mg per day was started. Apheresis with a staphylococcal protein A immunoadsorption column (Prosorba, Cypress Bioscience, Inc.) was initiated on Day 18 and was performed twice weekly for a total of six treatments. Cyclophosphamide was continued for a total of 14 days. His transfusion requirement ceased by the third immunoadsorption treatment. Forty units of RBCs were required over 23 days in an attempt to maintain a Hct greater than or equal to 15 percent.

Conclusion: Refractory autoimmune hemolysis can be a life-threatening event. The patient did not achieve a response until after several different therapeutic modalities were instituted, including plasmapheresis with a staphylococcal protein A column (Prosorba). A complete response continues to be durable for more than 1 year after therapy.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adrenal Cortex Hormones / therapeutic use*
  • Anemia, Hemolytic, Autoimmune / complications
  • Anemia, Hemolytic, Autoimmune / drug therapy
  • Anemia, Hemolytic, Autoimmune / surgery
  • Anemia, Hemolytic, Autoimmune / therapy*
  • Angina, Unstable / etiology
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Blood Transfusion*
  • Combined Modality Therapy
  • Drug Resistance
  • Hemagglutinins / blood
  • Hemagglutinins / immunology
  • Hematopoiesis, Extramedullary
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunosorbent Techniques*
  • Immunosuppressive Agents / therapeutic use*
  • Jaundice / etiology
  • Male
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Plasmapheresis*
  • Prednisone / therapeutic use*
  • Remission Induction
  • Spleen / abnormalities
  • Splenectomy*
  • Staphylococcal Protein A
  • Syncope / etiology

Substances

  • Adrenal Cortex Hormones
  • Autoantibodies
  • Hemagglutinins
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Staphylococcal Protein A
  • Prednisone
  • Methylprednisolone